Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Mar 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different cancers respond to new treatments known as targeted therapies and immune checkpoint inhibitors. These treatments have shown promise in improving outcomes for patients with difficult-to-treat cancers like breast cancer, lung cancer, melanoma, and others. However, researchers want to better understand why some patients don’t respond to these therapies and why some experience significant side effects. By identifying certain biological markers that can predict treatment responses, the goal is to make it easier for doctors to choose the best therapy for each patient.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of any type of cancer. You will also need to provide written consent and meet specific criteria outlined by the researchers. If you join the study, you can expect to undergo a diagnostic biopsy and provide samples for analysis. The trial aims to improve how treatments are selected, ultimately helping patients receive more personalized care. It's important to know that certain health conditions or treatments may exclude you from participating, so discussing eligibility with your doctor is a good idea.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age\>18 yrs old
• • histological diagnosis of any cancer
• • signed informed consent
• • fulfills criteria described in cohort definition
• • Clinical indication for a diagnostic biopsy
• Exclusion Criteria:
• • Performance Status (ECOG) \>2
• • life expectancy \< 3 months
• • unwilling to receive treatment at IEO for at least 6 months after enrolment
• • active pregnancy at the moment of enrolment
• • for cohort F: use of steroids (higher than 10 mg prednisone-equivalent) or other major immunosuppressive drug (e.g. tocilizumab) in the 14 days prior to the baseline sample collection.